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I. Abstract 
In adult vertebrates, all blood cells originate from hematopoietic stem cells, 
produced from hemangioblasts at the fetal stage. The hemangioblast, located within the 
yolk sac in the embryo, produces hematopoietic stem cells, early erythroblasts, 
macrophages, and vascular endothelial cells by a process called as primary 
hematopoiesis. Subsequently, hematopoietic stem cells are generated in the liver, 
allowing secondary hematopoiesis to continue even after achieving adulthood. During 
primary hematopoiesis in mammals, birds, amphibians, and teleost fishes, major 
transcription factors such as GATA1, GATA2, and SCL are expressed in the 
hemangioblast. Fetal-type globin genes, which are the targets of these transcription 
factors, are expressed during erythroblast differentiation. However, the mechanisms by 
which hemangioblasts specifically differentiate into erythroblasts during primary 
hematopoiesis are unclear. I selected the Xenopus laevis model due to the ease in 
inducing organ formation to identify specific genes whose time-specific expression 
would allow differentiation between hemangioblasts and erythroblasts. I identified a 
heme synthetase, aminolevulinic acid synthase gene (alas2). In this study, I investigated 
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the function of Xenopus alas2 (Xalas2) and showed that Xalas2 mediated erythroblast 
differentiation in primary hematopoiesis by regulating hba3 expression. 
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II. Abbreviations 
ALAS: aminolevulinic acid synthase 
aVBI: anterior VBI 
BB/BA: enzylbenzoate / benzyl alcohol 
BFU-E: erythroid burst-forming units 
BSA: Bovine serum albumin 
DHS: DnaseI hypersensitive site 
DLP: dorsal lateral plate 
CFU-E: erythroid colony-forming units 
DNA: deoxyribonucleotic acid 
EDTA: ethylenediaminetetraacetic acid 
EGFP: enhanced green fluorescent protein 
EGTA: ethylene glycol tetra acetic acid 
FBS: fetal bovine serum 
hba 3: -globin 3 
HRP: horseradish peroxidase 
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IL: interleukin 
IGF-1: insulin-like growth factor-1 
IRE: iron-responsive element 
IRP: IRE-binding protein 
KLF1: kruppel-like factor 1 
MBSH: 1×high-salt modified Barth's saline 
MEMFA: magnesium sulfate/formaldehyde buffer 
MO: antisense morpholino oligonucleotide 
MT: myc taq 
NF-E2: nuclear factor erythroid-derived 2 
OCD: ornithine decarboxylase 
pVBI: posterior VBI 
PVDF: Polyvinylidene DiFluoride 
RACE: Rapid Amplification of cDNA Ends 
RNA: ribonucleotic acid 
RT-PCR: reverse transcription-polymerase chain reaction 
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SCL: stem cell leukemia 
SDS–PAGE: sodium dodecyl sulfate -polyacrylamide gel electrophoresis 
TBST: Tris-buffered saline with Tween® 20 
UTR: untranslated region 
VBI: ventral blood island 
VMZ: ventral marginal zone 
WISH: whole mount in situ hybridization 
X. laevis: Xenopus laevis 
Xalas2: Xenopus delta-aminolevullnate synthase 2 
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III. Introduction 
III-1. The mechanism of erythrocytosis  
 Vertebrate hematopoietic development consists of two phases: primitive and 
definitive. In mice, progenitors of the primitive erythrocyte lineage arise from the 
mesoderm during gastrulation in the yolk sac region, called the blood island (Palis et al 
2001), (Baron et al 2013). Subsequently, definitive hematopoiesis involving the 
production of primitive erythrocytes occurs first in the aorta-gonad-mesonephros, 
second in the placenta during embryogenesis, and finally in the fetal liver (Tsiftsoglou 
et al 2009). Primitive hematopoiesis results in the formation of erythroblasts, 
megakaryocytes, and macrophages in the yolk sac (Tober et al 2007). The nuclei and 
hemoglobin of these erythroblasts are comprised of a heterotetramer of two α- and 
β-subunits of globin-containing heme (Palis et al 2014). At this stage, the β-subunit 
globin exists in the fetal form, εy-globin (Wilber et al 2011). Enucleated erythrocytes 
are produced at the definitive hematopoiesis stage in the fetal liver. After birth, 
β-subunit hemoglobin of the adult type is produced in enucleated erythrocytes within 
the bone marrow (Tsiftsoglou et al 2009). 
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The developmental mechanism differs between primitive and definitive 
erythrocytes. In the mouse, cytokines including interleukin (IL)-3, stem cell leukemia 
(SCL), and insulin-like growth factor-1 (IGF-1) act on hematopoietic stem cells during 
definitive hematopoiesis. These cells differentiate into erythroid burst-forming units 
(BFU-E), which express transcription factors Pu.1, GATA2, and SCL. Subsequently, 
erythropoietin specifically causes not only differentiation into erythroid colony-forming 
units (CFU-E) but also proliferation. CFU-E, expressing GATA1, GATA2, SCL, Sox6, 
nuclear factor erythroid-derived 2 (NF-E2), and kruppel-like factor 1 (KLF1) 
differentiate into pro-erythrocytes (Baron 2013). In contrast, erythroblast progenitors 
express fetal liver kinase 1 (Flk1), c-kit, Etv2, SCL, vascular endothelial (VE)-cadherin, 
and Tie2 during primitive hematopoiesis (Baron 2013). These cells have the ability to 
differentiate into both, endothelial, or hematopoietic cells. Furthermore, erythroblast 
progenitors also express adhesion proteins on their surface, such as CD44 (hyaluronan 
receptor) and integrins α4, α5, and β1 in the yolk sac (Isern et al 2011). In fact, tight 
associations within erythroblast progenitors have been observed in the yolk sac using 
electron microscopy (Haar and Ackerman 1971). Expression of these adhesion proteins 
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and increase in metalloprotease expression were lost before entering into blood vessel. 
However, the mechanism of hemangioblast differentiation into erythroblasts in terms of 
signal pathways before entering the bloodstream is unclear.  
III-2. The role of ALAS2 in vertebrate erythrocytosis 
 In vertebrates, the main function of the erythrocyte involves transport of 
oxygen via hemoglobin. Hemoglobin consists of a heterotetramer of two α- and 
β-subunits of globin carrying a synthesized heme complex, consisting of divalent iron 
(FeII) and porphyrin. However, heme also regulates several biological processes 
through heme-responsive or heme-sensitive proteins (Sun et al 2004). Heme controls 
erythrocyte differentiation independently as a transcriptional regulator with the 
exception of forming a complex with globin protein. For example, heme-regulated 
eIF2α kinase regulates translational initiation in diverse stress conditions by 
phosphorylation of the α-subunit of eIF2, activation of Atf4 signaling pathway in 
reducing oxidative stress, and in erythropoiesis (Rajeasekhar et al 2012). In addition, 
heme-mediated transcriptional activation of heme oxgenase-1 and globin gene through 
transcription repressor Bach1 in murine erythroleukemia cells (Furuyama et al 2007).  
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The detailed mechanism of hemoglobin synthesis in the mammalian 
erythrocytes has been studied previously. The heme synthesis pathway is evolutionarily 
conserved in vertebrates (Ajioka et al 2006). Two aminolevulinic acid synthase (ALAS) 
isozymes are encoded by ALAS-1 (also known as non-specific ALAS), which is 
nonspecifically expressed in adult mammals, and ALAS-2 (also known as erythroid 
ALAS), which is specifically expressed in erythroid cells (Riddle et al 1989). In the 
mouse, Alas2 transcription is regulated by iron and iron-related proteins. Alas2 
5-untranslated region (UTR) contains an iron-responsive element (IRE; 5-CAGUGX-3) 
(Melefors et al 1993) similar to that found in man, mouse, rat, and chicken. IRE-binding 
protein (IRP) binds to IRE-sequences in ALAS2 (Kim et al 1996). Alas2 translation is 
inhibited by forming of a stem-loop structure with IRE under conditions of low iron 
concentration. In the presence of high iron concentration, iron forms complexes with 
IRP and inactivates it, therefore IRP does not bind to IRE. The translated Alas2 moves 
from the cytosol to mitochondria and the pre-sequence including mitochondria transport 
signal is cleaved by ALAS to release the mature protein enzyme -ALA, followed by 
a catalytic series that leads to the formation of heme. This catalytic series is mediated by 
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ALA dehydratase, porphobilinogen deaminase, uroporphyrinogen III synthase, 
uroporphyrinogen decarboxylase, coproporphyrinogen oxidase, protoporphyrinogen 
oxidase, and ferrochelatase in the mitochondria and cytosol. ALAS2 is essential for 
heme synthesis in erythrocytes and deletion of the C-terminal of ALAS2 causes 
X-linked dominant protoporphyria in humans.  
 Few in vivo studies have been reported regarding the function of Alas2 in 
developmental biology, especially during primary hematopoiesis, which occurs in the 
yolk sac in vertebrates. Alas2-knockout mice exhibited formation of abnormal 
erythrocytes, accumulation of iron, and decrease in globin protein at embryonic day 
10.5 (E10.5), resulting in death due to anemia at E11.5 caused by defective hemoglobin 
(Nakajima et al 1999). These data demonstrated the role of Alas2 function in 
erythrocyte production during both, primary and definitive hematopoiesis. In a study in 
zebrafish, reduction of hemoglobin was confirmed by staining with o-dianisidine in case 
of mutations in sauternes (sau) gene, orthologue of mouse Alas2. Additionally, 
erythroblasts generated by definitive hematopoiesis were immature (Beownlie et al 
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1998). However, the role of ALAS2 in erythroblast differentiation in vertebrates during 
primary hematopoiesis is unknown. 
 Xenopus (frog), chicken, and quail are frequently used as hematopoiesis 
models because of species-specific advantages. Xenopus laevis is particularly useful for 
large-scale screening and functional analyses. Eggs are available year-round and 
artificial fertilization is easy to perform. In addition, extensive information regarding 
Xenopus cleavage patterns and fate map is available. Moreover, the transparent tadpole 
is suitable for observation of blood cells. Primitive hematopoiesis in X. laevis begins at 
the neurula-stage mesoderm in the ventral blood island (VBI). The primitive VBI 
expresses hematopoietic and endothelial markers, Flk-1, Fli-1, and Gata2 at the neurula 
stage, comparable to the hemangioblast in mammals. The VBI, equivalent to the yolk 
sac blood island of amniotes, produces a primitive erythroblast, which is released for 
circulation into peripheral blood vessels through the vitelline vein. VBIs have 
discernable anterior and posterior regions. Progenitors of the anterior VBI (aVBI) are 
derived from the dorsal marginal zone, while those of posterior VBI (pVBI) are derived 
from the ventral marginal zone (Ciau-Uitz et al 2000). Myeloid genes such as SpiB and 
 12 
Mpo are expressed in aVBI, whereas erythroid genes such as Runx, Lmo2, and Scl (tal1) 
are expressed in pVBI during the neurula stage (Costa et al 2000 and Walmsley et al 
2008). The erythroblast progenitors in pVBI express the mature marker, larval globin. 
However, the mechanism of differentiation into mature erythrocytes with respect to the 
signal pathway, before entering the bloodstream remains unknown. 
In this study, I explored whether ALAS2 has functions other than heme 
synthesis in primitive hematopoiesis based on heme transcription regulation. I showed 
that Xenopus alas2 (Xalas2) is first expressed in primitive erythroblast during primary 
hematopoiesis before transcription of embryonic globin. Moreover, by comparing the 
effect of synthesis inhibitor with Xalas2 translational inhibition, I demonstrate that 
Xalas2 independently controls the differentiation of erythroblast in primitive 
hematopoiesis via a heme-mediated independent mechanism. 
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III-3. Objective of this study 
The mechanism of hemangioblast differentiation into mature erythrocytes 
with respect to the signal pathway, before entering the bloodstream is currently 
unknown. Using Xenopus laevis as model organism, I identified Xalas2, a gene with 
time-specific expression that allows for distinction between hemangioblasts and 
erythroblasts. The purpose of this study was to determine the role of Xalas2 in 
erythroblast differentiation during primary hematopoiesis.  
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IV. Materials and methods 
IV-1. Animals  
This study was conducted in accordance with the Guideline for Proper 
Conduct of Animal Experiments by the Science Council of Japan. All experiments were 
performed at the National Institute of Advanced Industrial Science and Technology 
between 2012 and 2015. 
IV-2. Embryo culture and manipulation 
The adult frogs (X. laevis) of both sexes, were purchased from Watanabe 
Zoushoku and Hamamatsu Seibutsu Kyouzai. Adult female frogs were maintained in an 
incubator (Panasonic) at 21°C-23°C for approximately more than 13 hr after being 
injected with 100 U/ml human chorionic gonadotropin (Gestron; Kyoritsu Seiyaku) to 
obtain eggs. On the same day, adult male frogs were placed in ice-cold water to 
simulate a semi-hibernation state and testes were collected. The testes were stored in 
fetal bovine serum (FBS; Millipore) containing 10% Steinberg's solution (17% NaCl, 
0.5% KCl, 0.5% CaCl2, and 1.025% MgSO4) at 4°C until use. A fresh suspension of 
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sperm was prepared by mincing testes in De Boer's solution (0.11 M NaCl, 0.0013 M 
KCl, 0.00044 M CaCl2 NaHCO3) immediately before fertilization. Eggs were obtained 
from the cloaca of the injected female frog by applying pressure ventrally. The eggs 
were mixed with sperm in a petri dish and left standing for 6 min at RT for fertilization. 
Fertilized eggs were cultured in 0.5% De Boer's solution. Subsequently, the embryos 
were de-jellied using 1% sodium thioglycollate (Tashiro et al 1999) and washed several 
times with 10% Steinberg's solution. The embryos were then injected with each 
nucleotide in 1× high-salt, modified Barth's saline (MBSH)/5% Ficoll. The culture 
medium of the embryos was replaced with 10% Steinberg's solution before gastrulation.  
IV-3. RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was extracted from embryos and adult organs using phenol 
method as previously described (Ito et al 2001). Briefly, embryos or organs frozen 
under liquid nitrogen were crushed in homogenization solution (100 mM Tris-Cl, 50 
mM NaCl, 10 mM ethylenediaminetetraacetic acid [EDTA], and 0.5% sodium dodecyl 
sulfate [SDS]), supplemented with 20 mg/ml Proteinase K (Sigma-Aldrich), followed 
by incubation at 37°C for 1 hr. The solution was extracted with phenol/chloroform 
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(TE-saturated), followed by chloroform and 5 M ammonium acetate was added to the 
aqueous phase. The mixture was stored at 0°C and centrifuged for 20 min. 
Nuclease-free water, 3 M ammonium acetate (pH 5.2), and 100% ethanol was added to 
the RNA extract, centrifuged, and rinsed with 70% ethanol. First-strand cDNA was 
synthesized from extracted total RNA using an oligo-(dT) primer and SuperScript™ III 
RT (Life Technologies). The resulting cDNA was used as a template for reverse 
transcription-polymerase chain reaction (RT-PCR). Ornithine decarboxylase (ODC) 
gene was used as a positive control. For cloning of various globin cDNA, sequence 
information for globin primers were obtained from Xenbase genome database 
(http://www.xenbase.org/entry/). RT-PCR was performed using KOD-plus-neo kit 
(Toyobo) as described in manufacture instructions. The amplified globin cDNA were 
cloned into pBluescript II SK+ vector and sequences were analyzed by 3500 Genetic 
Analyzer (Thermo Fisher) to identify high-homology sequence of each gene. All primer 
sequences used for cloning are listed in Table 1. 
IV-4. RNA synthesis in vitro. 
The clones of Xalas2 mRNA (accession No: BC080015) and RhoBTB mRNA 
 17 
(NM_001092210) were purchased from Thermo Fisher Scientific K.K (Open 
Biosystems). These sequences were sub-cloned in pCS2 vectors. The plasmids PCS2 
dkk1, pCS2 EGFP, and pCS2 Red-gal were obtained from Dr. Asashima. These 
plasmids were digested with Not 1 (Takara), and capped RNA was synthesized using 
mMESSAGE mMACHINE® SP6 Kit (Life Technologies). After synthesis and DNase I 
treatment, 20 μl RNA solution was mixed with 250 l nuclease-free water and 30 l 
ammonium acetate (3 M, pH 5.2), and extracted with phenol/chloroform 
(Tris-EDTA-saturated), followed by extraction with chloroform. The aqueous layer of 
the extract was mixed with 1 volume isopropanol and centrifuged. Precipitated RNA 
was rinsed in 70% ethanol and purified by repeating isopropanol precipitation. Quality 
of the synthesized RNA was confirmed by gel electrophoresis and concentration of 
RNA was measured at 260 nm absorbance using a Nano Drop (Thermo Fisher).  
IV-5. Explant culture 
The embryos injected with messenger RNA (mRNA) were cultured up to 
Stage 10. The ventral marginal zone (VMZ) of the embryo was cut using a 
tungsten-needle in MBSH/1% bovine serum albumin (BSA) solution. The VMZ were 
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cultured with MBSH/1% BSA supplemented with 4-Methylumbelliferone until Stage 
23 and then frozen under liquid nitrogen. 
IV-6. DNA microarray 
Total RNA was isolated using the same method from each VMZ as IV-5. 
Complementary cRNA was synthesized from total RNA, labeled with Cy3-dye, and 
microarray analysis was conducted using Xenopus Oligo microarrays (G2514F, 
Agilent). Each sample was hybridized with one-color protocol and florescence signals 
were detected using a G2514F microarray scanner system (Agilent). These data were 
analyzed by GeneSpring GX10 software (Agilent).  
IV-7. MO design and activities 
I identified Xalas2 5’-UTR sequence by 5’rapid amplification of cDNA ends 
using SMARTerTM Rapid Amplification of cDNA Ends (RACE) cDNA Amplification 
Kit (Clontech), Xalas2-morpholino antisense oligonucleotide (xalas2-MO) was 
designed as described by Gene Tools, LLC (https://store.gene-tools.com). MO 
sequences were as follows: Xalas2a-MO, 
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5’-ACGATTAATGAGAGAAGCCATGTTC-3’, and Xalas2b-MO, 
5’-CAACGATTGATGAGAGAAGCCATGT-3’. I amplified Xalas2 coding sequence 
with 5’-UTR or 5 point-mutations in the morpholino binding site by RT-PCR with 
high-fidelity DNA polymerase, Pfu (Promega), using primers listed in Table 2. The 
amplified fragments were digested with BamHI and ClaI, and subcloned into the 
BamHI and ClaI sites of the pCS2+MT vector. Two types of Xalas2 RNA were 
synthesized in vitro using pCS2-5’-UTR-Xalas2-5myc and pCS2-5mis-Xalas2-5myc. 
To confirm the specificities of the MO, 2-cell stage embryos were injected with RNA 
and MOs, embryos were collected at Stage 9, and frozen in liquid nitrogen. The proteins 
of these embryos were extracted and separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS–PAGE). The proteins were transferred 
to PVDF membranes using iBlot dry blotting system (Life Technologies), and blocked 
with 10% skim milk (Nacalai Tesque) in Tris-buffered saline with Tween 20 (TBST) 
buffer (20 mM Tris–HCl [pH 7.6], 150 mM NaCl, and 0.05% Tween 20) overnight at 
4°C. The membranes were incubated with SC-40 HRP-conjugated, Myc (19E10), 
mouse monoclonal antibody (Santa Cruz) diluted at 3000-fold in 10% skim milk/TBST 
 20 
for 1 hr at room temperature, the membrane were washed 4 times with TBST and 
incubated with enhanced chemiluminescent assay reagent, SuperSignal West Femto 
(Pierce). The protein bands were visualized using an LAS1500 Analyzer (Fuji Film). 
The antibody was stripped from the membrane using stripping buffer (100 mM 
2-mercaptoethanol, 2% SDS, 62.5 mM Tris-Cl [pH 6.7]). The membranes were 
re-probed with monoclonal anti-actin clone antibody AC-40 (Sigma Aldrich) as loading 
control diluted at 3000-fold in 10% skim milk/TBST for 1 hr at room temperature. The 
membranes were washed three times and probed with horseradish peroxidase 
(HRP)-conjugated anti-mouse IgG (H&L) antibody (Cell Signaling) diluted at 
3000-fold as secondary antibody for 1 hr. The membranes were washed several times, 
visualized as described above. 
IV-8. Whole-mount in situ hybridization (WISH) 
The plasmids, pCMV-Sport6/Xalas2, pCMV-Sport6/RhoBTB, pGEM-T easy 
hba3 (NM_001086328), pGEM-T Gata1 (NM_001085640), pGEM-T Gata2 
(NM_001090574), and pBluescript II Sk-/SCL (Inui et al 2006) (NM_001088277 
NM_001088278) were digested with restriction enzymes, as listed in Table 3. All 
 21 
probes were synthesized using DIG RNA Labeling Mix (Roche), as listed in Table 3. 
The embryos were processed for whole-mount in situ hybridization as previously 
descried (Harland 1991); some embryos were embedded in paraffin, cut into 10-m 
sections, and stained with eosin. 
IV-9. Hemoglobin staining and transparent clearing 
Whole-embryo staining for heme expression was performed using 
o-dianisidine (Sigma Aldrich) histochemistry as previously described (Detrich et al 
1995). After staining, the embryos were fixed in MOPS/EGTA/MEMFA for 3 hr and 
incubated in BB/BA for a few days. 
IV-10. Collection of peripheral blood from larvae and Giemsa staining  
The larva tails at Stage 42 were cut in 10% Steinberg’s solution containing 
0.5% BSA and 10 IU/ml heparin (Devorah et al 2006). Peripheral blood was collected 
into tubes and centrifuged at 2,000 rpm at room temperature for 10 min. Concentrated 
blood cells were smeared onto a slide, fixed with 100% methanol for a few minutes 
after drying, and stained with Giemsa solution (Wako) as per manufacturer instructions.  
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Table 1: Primer sequence for RT-PCR 
Gene 
name 
Primer sequence 
X las2a Fw: 5’-ATCTTCACAACAAGGATGCA-3’ 
 Rv: 5’-GTTATATTGGGAAAGGAGGAC-3’ 
Xalas2b Fw: 5’-GCCTGAAGAAGAAATTTCTAG-3’ 
 Rv: 5’-AAAGCAGGAGGAGAAAAGAAG-3’ 
ODC Fw: 5’-GTCAATGATGGAGTGTATGGATC-3’ 
 
 
 
Rv: 5’-TCCAATCCGCTCTCCTGAGCAC-3’ 
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Table 2: Primer sequence for MO design and activities 
Gene name Primer sequence 
Injected Xalas2a Fw:5’-CCGGATCCAGTGCAGGGCAACAGAAAC-3’ 
 Rv:5’-CCATCGATCAGAGGCATACATAGTAATGTATTTT-3’ 
Injected Xalas2a 
5mis  
Fw:5’-CCGGATCCATGGCATCACTGATAAATCGATGTCCC-3’ 
 Rv:5’-CCATCGATCAGAGGCATACATAGTAATGTATTTT-3’ 
Injected Xalas2b  Fw:5’-CTTGACGTGTGAACATGGCTTCTCTCATCAATCG-3’ 
 Rv:5’-GTGTCTGTTGCCCTGCACTG-3’ 
Injected Xalas2b 
5mis  
Fw:5’-CCGGATCCATGGCATCACTGATAAATCGATGTCCC-3’ 
 Rv:5’-CCATCGATCAGAGGCATACATAGTAATGTATTTT-3’ 
 
Table 3: Details of WISH probes 
Gene name Restriction enzymes RNA polymerase Length (bp) 
Xalas2 NotI T7 2529 
RhoBTB SmaI T7 4499 
hba3 SpeI T7 202 
Gata1 EcoRI T7 1080 
Gata2 XbaI T7 1362 
Scl SacII T3 762 
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V. Results 
V-1. Alignment of Xalas2 
I cloned 5’-UTR sequences by RACE method and determined the coding 
sequence for Xalas2. The amino acid sequence was compared with that of other 
vertebrates. Xalas2 contains 2 heme-regulatory motifs (CP motif: [Arg, Lys, or 
Asn]-Cys-Pro-[Lys or hydrophobic residue]-[Lue or Met]) (Figure 1). CP motifs in the 
mitochondrial pre-sequence of ALAS-1 and ALAS-2 proteins have been reported to 
bind heme (Furuyama et al 2007). Furthermore, pre-sequences contain a signal that 
targets mitochondria in mammalian species (Furuyama et al 2007), but quite different 
from those found in aquatic animals (Figure 1). The green arrowhead indicates the 
processing site of precursor protein by peptidase (Lathrop et al 1993), and the blue 
square shows the catalytic region for synthesis of 5-aminolevulinic acid from glycine 
and succinyl coenzyme A (Figure 1). This region in X. laevis shows homology with 
these of human, mouse, and zebrafish.  
V-2. Xalas2 expression 
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Firstly, Xalas2 expression during early developmental stages was investigated 
using RT-PCR. The Xalas2a mRNA expression was detected from Stage 15, 
continuously induced until Stage 34, and maintained its level until Stage 42. Compared 
with Xalas2a, Xalas2b began to be expressed after Stage 38, when pro-erythrocytes 
entered circulation (Figure 2A). To analyze the spatiotemporal expression of Xalas2, I 
performed whole mount in situ hybridization. Xalas2a was expressed in anterior 
mesoderm at the neurula stage (Figure 2B, C). This expression was very similar to that 
of transcription factor, Scl (Figure 2K). SCL forms a transcriptional complex with E47, 
Lbd/NL1, LMO2, and GATA-1 to regulate hematopoiesis factors (Wadman et al 1997) 
and acts in the early anterior mesoderm to activate hematopoietic stem cells in Xenopus 
laevis (Mead et al 1998). At Stage 23, it was clearly shown that Xalas2a expression 
pattern was similar to that of Scl, two crossing lines for cardiac mesoderm and 
hemangioblast at Stage 23 (Figure 2D, D’, L). Xalas2a was continuously expressed in 
the VBI and disappeared from the anterior cardiac region at approximately the tailbud 
stage (Figure 2E, E’). These expression patterns were similar to those of hba3 (Figure 
2I), one of the globin genes observed in the VBI before the cells entered the circulation. 
 26 
The expression of Xalas2 at Stage 38 was observed in the aortic arc near the cardiac 
region and the liver (Figure 2F, F’). These results suggested that Xalas2 was expressed 
in circulating pro-erythroblasts and erythroblasts within certain blood vessels at the 
tadpole stage. Interestingly,  
V-3. Translational inhibition of Xalas2 leads to loss of hemoglobin 
I inhibited in vivo translation of 2 types Xalas2 using Xalas2-MO as designed 
in Figure 3A and 3B. The blastomere in dorsal vegetal at the 8-cell stage is committed 
to the fate of hemangioblast at Stage 23. In contrast, an erythroblast precursor in the 
aVBI region at Stage 34, will not undergo further development in these tissue cells 
(Figure 3A and 3B). Staining of hemoglobin in the embryos injected with this MO by 
o-dianisidine confirmed the function of Xalas2 during heme synthesis in erythroblast 
precursors and erythroblasts, at Stages 34 and 42, respectively (Figure 5A). Hemoglobin 
was hardly observed in the embryo after Xalas2 MO injection in the 8-cell ventral 
vegetal-side at both 23 and 34 Stages. In particular, very few blood cells were seen 
within the cardiac atrium and ventricle at Stage 42, as in Figure 5B, lower panel. On the 
other hand, in the embryos injected into the dorsal vegetal side, hemoglobin levels 
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within the heart were decreased, compared with the control MO injected embryo 
(Figure 5A, lower panel). I inhibited heme synthesis pathway using an alternate method 
to verify whether biosynthesis of heme itself caused reduction of hemoglobin in vivo. 
Since succinylacetone is structurally similar to aminolevulinic acid, addition of 
succinylacetone competitively inhibits porphobilinogen synthase-dependent conversion 
of heme synthesis (Figure 6A). I found that amount of hemoglobin complex was 
decreased with an increase in dose of succinylacetone (Figure 6B). Particularly, at 0.25 
mM succinylacetone, hemoglobin complexes disappeared altogether, in the erythroblast 
precursors at Stage 34 (Figure 11B) and in the circulating erythroblasts at Stage 42 
(Figure 6B). While the addition of more than 0.25 mM succinylacetone resulted in 
non-specific phenotypes including edema, loss of a few somites, convulsion, and 
embryonic death before gastrulation, the optimal concentration (0.25 mM) of 
succinylacetone also showed similar phenotypes, albeit to a lesser extent, in addition to 
loss of hemoglobin. 
V-4. XAlas2 controls the differentiation of erythroblasts  
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Next, involvement of Xalas2 in erythroblast differentiation was confirmed by 
knockdown of 2 types of Xalas2, MO1 and MO2, which were injected into 2 
blastomeres at the dorsal-vegetal or ventral-vegetal side at the 8-cell stage. The 
expression of Scl in the hemangioblast in Xalas2 MO-injected embryo was not affected, 
as that in the control MO-injected embryos at Stage 23 (Figure 7A and 7B, left panel), 
By contrast, the expression of Scl was decreased in the aortic arch in the embryo 
injected with Xalas2 MO at the dorsal vegetal region at Stage 34 (Figure 7A). 
Additionally, Scl expression disappeared in pVBI in the ventral vegetal region (red 
arrow in Figure 7B). Regarding hba3, V-shaped expression was somewhat diminished 
at Stage 34 in the aVBI in the embryos injected with Xalas2 MO on the dorsal side 
(Figure 8A and 9A). However, in the aVBI, there was no difference in hba3 expression 
between the embryos injected with the control MO and Xalas2 MO (Figure 9A). By 
contrast, after ventral vegetal injection, expression was greatly decreased in pVBI 
(Figure 8B and 9B), and the embryo with decreased in pVBI was observed at high 
frequency from 62% to 82% compared with the control MO injected-embryos from 0 to 
17% (Figure 9B and 9C). Injection of Xalas2 MO with Xalas2/5mis mRNA containing 
 29 
5 point-mutations in the MO binding site, rescued the expression of hba3 approximately 
by 44% (Figure 10). The expression of Gata1 and Gata2, which are transcription 
factors responsible for globin genes (Deconinck et al 2000), was not affected by Xalas2 
MO injection at Stages 23 and 34 (Figure 7B). In summary, inhibition of Xalas2 
translation did not affect development of hemangioblast at Stage 23 but impeded 
differentiation of erythroblast precursors (Figure 7, 8, and 10). Inhibition of Xalas2 
caused down-regulation of hba3 expression (Figure 8 and 10). These data suggest that 
Xalas2 functions in erythrocyte precursors of pVBI to regulate expression of hba3.  
V-5. Xalas2-regulated hba3 expression 
Next, I asked whether heme synthesized by Xalas2 causes downregulation of 
hba3 genes, I investigated the hba3 expression pattern in embryos treated with 
succinylacetone at Stage 34 (Figure 11A). The results showed that hba3 expression was 
not down regulated in embryos treated with succinylacetone (Figure 11B, right panel). 
By contrast, Xalas2-knockdown embryos showed significant down-regulation of hba3 
gene (Figure 11B, middle panel). Additionally, Scl, Gata1, and Gata2 were expressed at 
normal levels in the succinylacetone-treated embryo (Figure 12). Although, hemoglobin 
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was not detected in both condition (Figure 5B, 6B and 11B). These data suggest that 
hba3 expression may not be affected by heme synthesized by Xalas2. Abnormal 
function of heme as a transcription factor has been reported previously (Suragani et al 
2012); however, in this study heme does not regulate a-globin expression in vivo 
(Figure 11A).  
V-6. Xalas2 is required for the proliferation or/and differentiation of erythroblasts  
Translational inhibition of Xalas2 gene affected hba3 and Scl expression at 
Stage 34 in erythroblast precursors located on VBI as I showed (Figure 7B and 8B). 
Finally, in order to visualize circulating erythroblasts, GFP mRNA was injected in the 
ventral vegetal side at the 8-cell stage and a portion of erythroblast precursors in VBI 
were labeled by GFP. Circulation of the enhanced green fluorescent protein 
(EGFP)-labeled blood cells in each conditional embryo was analyzed (Figure 13A). The 
number of labeled erythrocytes was low in Xalas2 MO-injected and 
succinylacetone-treated embryos as compared with the control MO injected embryo.  
To examine the abilities of erythroblast precursors to differentiate into mature 
erythrocytes, circulating erythroblasts in the tadpoles were collected and their 
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morphology was analyzed by Giemsa staining (Figure 13B and 13C). In the control 
MO-injected tadpoles, characteristic small cells with nuclei were observed, similar to 
normal erythroblasts or basoerythrocytes. In contrast, in Xalas2 MO-injected tadpoles 
showed erythroblast precursor-like morphology including trachychromatic cytoplasm 
and enlarged nuclei. In the tadpoles treated with succinylacetone, characteristic small 
cells with nuclei were observed, similar to the control MO-injected tadpoles. However, 
the number of blood cells was dramatically decreased, and there was no leucosytes 
observed in the succinylacetone-treated embryos. Additionally, the rate of immature 
erythroblast was about 65.5% in Xalas2 MO-injected embryo. The value showed higher 
than in control MO-injected embryo and succinylacetone–treated (Figure 14). In 
contrast, the rate of mature erythroblast was respectively more than 63% in untreated 
embryo, control MO-injected and succinylacetone–treated. These data suggest that 
erythroblasts of Xalas2 MO-injected and succinylacetone–treated tadpoles show 
characteristic differences. Thus, I concluded that heme synthesized by Xalas2 does not 
regulate differentiation into erythroblast, rather Xalas2 may independently be 
responsible.   
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VI. Discussion  
Mammalian ALAS2 have been reported to be expressed specifically in 
erythrocytes that synthesize aminolevulinic acid as a heme mediator. Firstly, results 
from Xalas2 cloning and alignment show that Xalas2 contains 2 heme-regulatory motifs. 
The CP motif (Figure 1) on the pre-sequence protein, processed in the mitochondria, is 
widely conserved in vertebrates. These CP motifs bind to heme and prevent alas1 
processing within the mitochondria (Fukuyama et al 2007). Mitochondrial transport of 
mouse pre-alas2 protein has been shown to be inhibited by addition of exogenous 
hemin (Lathrop and Timko 1993). Xalas2 is thought to function similarly as mammal.  
Furthermore, 5’-UTR of alas2 contains an IRE sequence (5’-CAGUGX-3’) 
similar to that in human, mouse, rat, and chicken (Cox et al 1991). IRE found in the 
transcripts that encode iron metabolism proteins is recognized by IRP (Rouault and 
Klausner 1997), ALAS2 is also one of the iron metabolism proteins (Cox et al 1991 and 
Melefors et al 1993). The 5’-UTR of the IRE transcripts form a stem-loop structure, and 
translation of alas2 mRNA is inhibited in absence of iron. In contrast, in the presence of 
high concentration of iron, IRP does not bind to IRE, therefore alas2 mRNA can be 
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translated (Hentze et al 2004). Xalas2 is possibly regulated by iron and IRP in the 
embryos.  
The purpose of this study was to investigate the role of Xalas2 in erythroblast 
differentiation during primary hematopoiesis. Xalas2 was specifically expressed in the 
anterior mesoderm, hemangioblast, and erythroblast. Xalas2 expression during early 
development shows that other genes are involved in heme biosynthesis in Xenopus 
laevis. For example, it has been reported that Alad, Pbgd, Uro3s, and Urod have 
expressed in the egg stage (Shi et al 2008). Thus, these data suggest that Xalas2 is a 
rate-limiting enzyme for heme synthesis in other vertebrates (Shi et al 2008), however 
Xalas2 might have some function in hemangioblasts and pro-erythroblasts. Therefore, it 
is considered that Xalas2 could be involved in the differentiation from mesoderm to 
hemangioblast. In Xenopus embryos, Gata2 is required for hemangioblast formation by 
controlling Lmo and Scl (Liu et al 2008). However, Xalas2 inhibition did not affect 
expression of hematopoietic transcription factor, Scl and Gata2 in the hemangioblast. In 
contrast, Scl expression in VBI decreased and hba3 expression was inhibited with 
injection of Xalas2 MO in the erythroblast precursor region (Figure 7), which was not 
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observed with SA treatment (Figure 12). Scl is required for generation of erythrocyte 
and endothelial cells in not only hemangioblasts during primary hematopoiesis, but also 
in the dorsal lateral plate during definitive hematopoiesis (Mead et al 1998).  
Hba3 is an α-globin gene and Hba3 protein consists of hemoglobin α subunit 
in the Xenopus larva. It is reported that α-globin transcription is regulated by heme 
concentration (Tahara et al 2004 and Chiabrando et al 2014). When heme biosynthesis 
is inactive, the transcription of α-globin is inhibited by the repressor complex of Bach1 
and small Maf proteins that bind MAREs (Maf recognition elements) in the regulatory 
region of -globin genes. On the other hand, when heme biosynthesis is active, heme 
binds Bach1 in the nucleus and mediates its export to the cytosol. Then, erythroid 
transcription factor, NF-E2 p45 associates with small Maf proteins and activates the 
transcription of globin in K562 cells (Tahara et al 2004). In this study, hba3 expression 
was downregulated in Xalas2-knockdown embryos (Figure 11B, middle panel) but not 
in embryos treated with succinylacetone (Figure 11B, right panel). It is unclear why the 
in vitro and in vivo results differed; probably since K562, a chronic myelocytic 
leukemia cell line represents definitive hematopoiesis, whereas the data were obtained 
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with primary hematopoiesis in Xenopus embryos. The role of alas2 in cytosol and the 
nucleus is also unknown. Thus, my data suggest a larval regulatory pathway of hba3 
transcription by Xalas2, which is independent of heme, Bach1 pathway, and Gata-Scl 
transcription pathway.  
 In zebrafish and mouse, loss of ALAS2 function caused immature 
erythroblast formation and the differentiation of erythroblast was delay (Beownlie et al 
1998, Takahashi et al 1999). Especially, in the ALAS2 knockout mice, the present study 
demonstrated that low endogenous heme by loss of ALAS2 caused maturation arrest of 
primitive erythroid cells (Takahashi et al 1999). In this study, the Xalas2 MO-injected 
tadpoles also showed characteristic erythroblast precursor-like morphology including 
trachychromatic cytoplasm and enlarged nuclei (Figure 13C). By contrast, in the 
tadpoles treated with succinylacetone, an inhibitor of heme biosynthesis, characteristic 
small nuclei and cells were observed, similar to the control MO-injected tadpoles. 
Additionally, the inhibition of heme synthesis on both of conditions caused the number 
of cell to decrease.  Treatment of succinylacetone  These data suggest that heme 
synthesized by Xalas2 does not regulate differentiation into erythroblasts, rather Xalas2 
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may independently be responsible. Generally, while heme is reported to function as a 
transcription factor (Suragani et al 2012), it is no reports that alas2 makes 
transcriptional control. In recent years, it is suggested that the C-terminal region of the 
mature human ALAS2 can be modified by small ubiquitin-like modifier (SUMO) 
molecules (Kadirvel et al 2012). SUMO protein is highly conserved from yeast to 
mammalians (Chen et al 1998). In vertebrates, there are three major SUMO isoform 
(SUMO-1, SUMO-2, SUMO-3), which expressed in all tissues (Huang et al 2004). 
C-terminus in Glycine residue of SUMO has the region of isopeptide bond to the side 
chain of a particular Lys residue of the target protein (Hay 2005). In vitro, modification 
by SUMO2 and SUMO3 of actin is involved in nuclear translocation (Rosas-Acosta et 
al 2005). Various SUMO binding targets are reported in the cytoskeletal proteins, such 
as Rho family GTPase, actin and tubulin (Rosas-Acosta et al 2005 and Vertegaal AC et 
al 2004). Erythroblast progenitors in mouse also express adhesion proteins related 
cytoskeletal protein on their surface, CD44, integrins α4, α5, and β1 in the yolk sac 
(Isern et al 2011). Expressions of those were lost before entering into blood vessel. 
Additionally, Mouse with deletion of mDia2, a form in isoform and Rho effectors, fall 
 37 
to form actin filaments in erythroblasts (Watanabe et al 2013 and Kalfa et al 2014). 
There are no reports that these two molecules are modified by SUMO in erythroblasts. 
However, from above reports, ALAS2 with cytoskeletal proteins might regulate 
erythroblast differentiation by the modification with SUMO in primary hematopoiesis. 
In view of some possible mechanisms on mammalian, I think that XAlas2 protein might 
be located in cytoplasm by inhibition of transporting to mitochondria and subjected to 
some posttranslational modification, for example, by SUMO in this study. It might be 
possible that XAlas2 protein could regulate transcription of hba3, cell division and 
differentiation of erythroblast thereby.  
 The specific mechanism of transcriptional control by Xalas2 is not clear. 
However, in my study, the presence of a novel control mechanism of erythroid 
differentiation through the Xalas2 was suggested. These results are considered to be an 
important finding from the view point of evolutionary diversity of the hematopoietic 
system. 
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IX. Figures and Legends 
 
Figure 1. Alignment of Alas2 protein sequences of Xenopus (type A accession no. 
NP_001087499; type B accession no. AAH84616), human (accession no. NP_000023), 
mouse (accession no NP_033783), and zebrafish (accession no NP_571757). The 
yellow box indicates the heme regulatory motif (CP motif [Arg, Lys or 
Asn]-Cys-Pro-[Lys or hydrophobic residue]-[Lue or Met]). The blue box indicates the 
catalytic core domain. The green arrowhead indicates the site of precursor protein 
processing by mitochondrial peptidase. Amino acids indicated in red are conserved 
amino acid in Xenopus, human, mouse, and zebrafish. 
 
Figure 2. Xalas2 and erythrocyte-related gene expression in X. laevis embryos. (A) 
RT-PCR analysis of Xalas2 type a and b expression during Xenopus development. 
Ornithine decarboxylase (odc) served as an internal control. Whole-mount in situ 
hybridization analysis using Xalas2 antisense probe (B–F, D'–F', E', F''), hba3 (G–J, I', 
J'), and Scl (K–N). (B) Stage 15: ventral view shows weak Xalas2 expression in the 
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anterior mesoderm (arrowhead). (C) Stage 18: expression in the anterior mesoderm 
(arrowhead) is extensive, as viewed from the ventral side. (D, D’) Stage 23, (E, E’) 
stage 34: ventral, lateral views of the same embryo show extensive staining in the 
hemangioblast and ventral blood island (VBI) (arrows). (F, F’) Stage 38: expression of 
alas2 is distinct in the circulatory system (ventral and lateral views). Eosin-stained 
sections showing Xalas2 expression in stage 34 (E'') and stage 38 (F'') and hba3 in the 
same stages (I', J'). Transverse sections of embryos on the red lines in panels E'', F'', I', J’ 
are shown in panels E', F', I', J'. Scale bars in stages 15, 18, and 23 represent 0.5 mm; in 
Stages 34 and 38, 0.1 mm. 
 
Figure 4. (A) Xalas2-MO was designed to target the sequence around the translational 
start codon of both Xalas2 alleles (Xalas2a and Xalas2b). Xalas2a-MO/5mis and 
Xalas2b-MO/5mis have five mutations and serve as the negative control. Identical 
residues are indicated in red. (B) Western blot analysis of c-Myc-tagged XAlas2 
proteins in the embryos co-injected with the indicated mRNAs and MO. Actin was used 
as the internal control. Both alleles were targeted by Xalas2a MO and Xalas2b MO 
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(lane 2, 8). Xalas2a MO and Xalas2b MO/5mis failed to target these genes (lanes 5, 11).  
 
Figure 3. Region-specific translational inhibition of Xalas2 gene by the injection of 
red-gal and Xalas2 MO. Whole-mount in situ hybridization of Xalas2 and Red-gal 
staining were performed. (A) Upon dorsal vegetal injection, Xalas2 translation was 
inhibited in hemangioblasts at St23 (upper). (B) Upon ventral vegetal injection, Xalas2 
translation was inhibited in the ventral blood island at St34 (lower panel). 
 
Figure 5. Hemoglobin staining in Xalas2 MO-injected embryos and the control 
MO-injected embryos at Stage 42. (A) Schematic pathway of heme synthesis and 
inhibition of Xalas2 translation. These MOs were injected into (B) dorsal vegetal and 
(C) ventral vegetal in 8-cell stage. The red regions in the cartoon indicate the tissue 
where translation of Xalas2 was inhibited at Stage 23 and Stage 34. The figures on the 
lower line are enlarged pictures around the heart. Scale bars on upper line and lower 
line were 0.5 mm and 0.25 mm, respectively. 
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Figure 6. (A) Schematic of the heme synthesis pathway and inhibition of ALAD with 
succinylacetone. (B) Staining of hemoglobin in the embryos treated with 
succinylacetone at the indicated concentrations from the 8-cell-stage to Stage 42. 
Figures on upper panel show the picture of the head and body. The enlarged figure of 
the heart is shown on the lower panel. Scale bars in upper and lower figures are 0.5 mm 
and 0.25 mm, respectively. 
 
Figure 7. Expression of hematopoietic transcription factor in Xalas2 MO injected 
embryo. Embryos were microinjected with 40 ng of Xalas2 MO in the dorsal-vegetal 
side (A) and the ventral-vegetal side (B). Red colored region indicates the location of 
Xalas2 MO injected with either dorsal-vegetal side or ventral-vegetal side at 8-cel Stage. 
Whole-mount in situ hybridization of scl in Stages 23 and 34 (A and B), of Gata2 in 
Stage 23, and of Gata1 in Stage 34 (B) are shown. The block arrow indicates two 
crossing line in scl expression in control MO-injected embryo. The red arrow indicates 
decrease in scl expression in Xalas2 MO-injected embryo. The number of representative 
phenotypes among total number of injected embryos is shown at the left bottom corner 
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of each figure. The experiments were performed independently at least twice. Scale bars 
represent 0.5 mm.  
 
Figure 8. The expression of hba3 in Xalas2 MO-injected embryos. Embryos were 
microinjected with 40 ng Xalas2-MO in the dorsal-vegetal side (A) or the vegetal side 
(B). Whole-mount in situ hybridization of hba3 at Stages 23 and 34 are shown. The 
arrows indicate the loss of hba3 expression. The number of phenotypes among total 
number of injected embryos is shown at the lower left bottom corner of each figure. The 
experiments were performed independently more than three times. Scale bars represent 
0.5 mm.  
 
Figure 9. The hba3 expression was semi-quantitated in the embryo injected with 
control MO- or Xalas2 into dorsal vegetal side (A), ventral vegetal side (B). (A) 
Embryos expressing hba3 maintained the V-shape region (arrow) in VBI, designated as 
(+), and reduced embryos were counted as (-); “Other” represents an abnormal 
phenotype with hba3 expression. (B) Maintained expression of hba3 in the control 
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embryo in the whole posterior region was counted as (+). The expression observed in 
the posterior-and-midline VBI was counted as (+/-), and the expression in the anterior 
VBI was counted as (-). (C) Hba3 expression was semi-quantitated in the control MO- 
and Xalas2 MO-injected embryos into ventral vegetal side. The experiments were 
performed in three independent replicates. Student’s t-test was used to determine 
significant differences. P < 0.05 was taken as statistically significant. Scale bars 
represent 0.5 mm.  
 
 
Figure 10. Rescue of hba3 in Xalas2 MO-injected embryos by co-injecting 
MO-insensitive Xalas2a/5mis mRNA. (A) Xalas2a/5mis was designed with 5 point 
mutations. (B) Knockdown of Xalas2 caused low-level hba3 expression on VBI; this 
effect was reversed by co-expression of 1 ng of Xalas2a/5mis mRNA. Hba3 expression 
was rescued in the posterior (+) and midline VBI (+/-); (-), not rescued. Scale bars 
represent 0.5 mm.  
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Figure 11. Regulation of -globin transcription by heme biosynthesis. (A) Inhibition 
of ALAD by competitive substrate, succinylacetone. Heme-dependent-globin 
transcription reported by Tahara et al 2004 and Ogawa et al 2001. (B) Hemoglobin 
staining and hba3 expression in Xalas2 knock-down or succinylacetone treatment at 
Stage 34. The arrowhead indicates hemoglobin staining. All scale bars indicate 0.5 mm.  
 
Figure 12. Expression of hematopoietic transcription factor in the embryos treated with 
succinylacetone (SA) of 0.25 mM from the 8-cell-stage to Stage 34. Whole-mount in 
situ hybridization of scl and Gata2 in Stage 23 and of Gata1, hba3, and Scl in Stage 34 
are shown. Scale bars represent 0.5 mm.  
Figure 13. Xalas2 is essential for the development of mature erythroblasts. (A) 
Circulating EGFP-labeled erythroblasts in the embryos either injected with the 
control-MO or Xalas2-MO or treated by succinylacetone. (B) Representative 
morphology of blood cells stained by Giemsa. The blood cells were harvested from 
embryos at Stage 42. The arrowheads indicate circulating erythroblasts. (C) Enlarged 
views in each condition.  
 54 
Figure 14. The morphological difference in erythroblast after inhibition of heme 
biosynthesis. The representative morphology of blood cells stained by Giemsa. The 
blood cells were harvested from embryos at Stage 42. The cells are represented as cells 
observed in 58mm2. Scale bars represent 0.5 μm. 
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